Last reviewed · How we verify
NCT05387187
Evaluate the Effect and Safety of Pu Yang Wan Wu Tang and Western Medicine on Chronic Kidney Disease
Phase 2, PHASE3 trial testing Pu Yang Wan Wu Tang plus Pentoxifylline in Chronic Kidney Diseases in 40 participants. Status unknown.
31 May 2022
Quick facts
| Lead sponsor | Taipei Medical University Hospital |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 May 2022 |
| Primary completion | 31 May 2022 |
| Estimated completion | 20 June 2023 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Pu Yang Wan Wu Tang plus Pentoxifylline — full drug profile →
- Pentoxifylline — full drug profile →
Conditions studied
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
Sponsor
Taipei Medical University Hospital
Who can join
Adults 20 to 80, any sex, with Chronic Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The indication of Pu Yang Wan Wu Tang is stroke sequelae, such as half body paralysis, aphasia and muscle weakness. Pu Yang Wan Wu Tang is proved to have the effect of protecting nerve and blood vessel, anti-inflammation, anti-coagulation, dilating peripheral vessel, promot-ing micro circulation, improving hemodynamics, and activating central nerve system. Huangqi could attenuate podocyte injury by regulating the expression and distribu-tion of nephrin and podocin. Huangqi and Danggui are associated with fewer infiltra-tion of macrophages and limitation of renal intrinsic cell activation, which may lead to earlier and persistent reduction of proteinuria. This research will use the compound Chinese medicine, Pu Yang Wan Wu Tang. Those treatments combined Western medicine to assess the efficacy and drug safety on the CKD cases. Series of blood and urine were collected regularly during study to prove the role of Chinese medicine in the treatment of CKD, and to assess their drug safety. The final goal of the plan is to establish the new indication of Pu Yang Wan Wu Tang and enhance the interaction and cooperation between Chinese and Western medicine.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05387187
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Diseases
Currently open trials in the same condition.
- NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
- NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
- NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
- NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
- NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting
Other Taipei Medical University Hospital trials
Trials by the same sponsor.
- NCT07294469 — Menthol for Improving Movement and Sleep in Parkinson's Disease Patients · Phase 2 · not yet recruiting
- NCT07114289 — Spontaneous Breathing Trials Using Pressure Support or T-Piece in Overweight and Obese Patients · NA · recruiting
- NCT06949618 — Repetitive Transcranial Magnetic Stimulation in Cancer Pain Management · NA · not yet recruiting
- NCT05830578 — Clinical Validation of the Electrocardiogram Measurement · unknown
- NCT05877079 — TRPM8 in Acute Ischemic Stroke by Topical Menthol · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05387187 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Taipei Medical University Hospital
- Last refreshed: 26 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05387187.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing